Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMF86P2)

• Drug Name: BI 655064 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Lupus	4A40	Phase 2	[1]
Rheumatoid arthritis	FA20	Phase 1	[2]
Thrombocytopenia	3B64	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMF86P2

Molecule-Related Drug Atlas

Drug(s) Targeting TNF related activation protein (CD40LG)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
IL-2/CD40L-expressing leukemia vaccine	DMIHQ5G	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[4]
Lucatumumab	DMY2L7V	Lymphoma	2A80-2A86	Phase 2	[5]
Dapirolizumab pegol	DMIYFWA	Systemic lupus erythematosus	4A40.0	Phase 2	[1]
PG-102	DMF5YEN	Autoimmune diabetes	5A10	Phase 2	[6]
ISF35	DMBZK3P	Chronic lymphocytic leukaemia	2A82.0	Phase 2	[7]
CDP-7657	DMN8I5Q	Systemic lupus erythematosus	4A40.0	Phase 1	[8]
MEDI4920	DME7BMT	Rheumatoid arthritis	FA20	Phase 1	[9]
UltraCD40L	DMHG7DZ	Systemic lupus erythematosus	4A40.0	Phase 1	[10]
BPX-101	DM51MSD	Prostate cancer	2C82.0	Phase 1	[11]
Chi Lob 7/4	DMSOB5D	B-cell lymphoma	2A86	Phase 1	[12]

Drug(s) Targeting CD40L receptor (CD40)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
APX005M	DMX2P5G	Melanoma	2C30	Phase 2	[13]
ASKP-1240	DM1CLKO	Transplant rejection	NE84	Phase 2	[14]
CFZ533	DM1TWIE	Graves disease	5A02.0	Phase 2	[1]
Dazodalibep	DM7YII9	Kidney transplant rejection	NE84	Phase 2	[15]
Iscalimab	DMW4CR8	Type-1 diabetes	5A10	Phase 2	[16]
KPL-404	DMQJODL	Rheumatoid arthritis	FA20	Phase 2	[17]
AT-1501	DMQIA5K	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[18]
Frexalimab	DMMJTYP	Multiple sclerosis	8A40	Phase 2	[19]
SL-172154	DMN3D72	Ovarian cancer	2C73	Phase 1	[20]
GEN1042	DMNP6T3	Solid tumour/cancer	2A00-2F9Z	Phase 1	[21]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
CD40L receptor (CD40)	TTN6Y9A	TNR5_HUMAN	Inhibitor	[1]
TNF related activation protein (CD40LG)	TTIJP3Q	CD40L_HUMAN	Not Available	[3]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT02009761) Multiple Rising Does Study (Subcutaneous Doses) of BI 655064 in Male and Female Patients With Chronic Primary Immune Thrombocytopenic Purpura (ITP).. U.S. National Institutes of Health.
• [3] FRI0167 Patient-Reported Outcomes (PROS) During Treatment with Mavrilimumab, A Fully Human Monoclonal Antibody Targeting GMCSFR-Alpha, In the Phase IIB Earth Explorer 1 Study
• [4] Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and a... Blood. 2006 Feb 15;107(4):1332-41.
• [5] Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia.Leuk Lymphoma.2012 Nov;53(11):2136-42.
• [6] Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40.J Immunol.2015 May 1;194(9):4319-27.
• [7] Intratumoral injection of Ad-ISF35 (Chimeric CD154) breaks tolerance and induces lymphoma tumor regression. Hum Gene Ther. 2015 Jan;26(1):14-25.
• [8] CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study. Arthritis Res Ther. 2015 Sep 3;17:234.
• [9] ClinicalTrials.gov (NCT02151110) A Phase 1, Randomized, Blinded, Placebo-controlled, Single-ascending Dose Study to Evaluate the Safety and Tolerability of MEDI4920 in Healthy Adults. U.S. National Institutes of Health.
• [10] CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. Cancer Immunol Immunother. 2013 February; 62(2): 347-357.
• [11] Activation of antigen-exposed iMC-DCs at the ight place and ight time promotes potent anti-tumor immunity. Oncoimmunology. 2012 May 1; 1(3): 362-363.
• [12] Agonistic CD40 antibodies and cancer therapy
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1874).
• [15] The enhanced immunopharmacology of VIB4920, a novel Tn3 fusion protein and CD40L antagonist, and assessment of its safety profile in cynomolgus monkeys. Br J Pharmacol. 2020 Mar;177(5):1061-1076.
• [16] Developments in immunosuppression. Curr Opin Organ Transplant. 2021 Feb 1;26(1):91-96.
• [17] Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients. Arthritis Res Ther. 2021 Jan 6;23(1):5.
• [18] ClinicalTrials.gov (NCT04322149) A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS. U.S.National Institutes of Health.
• [19] ClinicalTrials.gov (NCT04879628) A Phase 2, Double-blind, Randomized, Placebo-controlled Study Assessing Efficacy and Safety of SAR441344, a CD40L-antagonist Monoclonal Antibody, in Participants With Relapsing Multiple Sclerosis. U.S.National Institutes of Health.
• [20] Clinical pipeline report, company report or official report of Shattuck Labs.
• [21] Clinical pipeline report, company report or official report of Genmab.